Mirum Pharmaceuticals, Inc. (MIRM) stock
MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$93.99+0.66 (+0.71%)
Close on Nov 13, 2026Market cap $6.10BP/E –Yield –
Mirum Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Mirum Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -139.2%. For fiscal 2025 it was -4.5%, against -26.1% the year before. The highest annual figure on record is -4.5% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4.5% | +21.6 |
| FY2024 | Dec 31, 2024 | -26.1% | +61.6 |
| FY2023 | Dec 31, 2023 | -87.7% | +88.4 |
| FY2022 | Dec 31, 2022 | -176.0% | +262.8 |
| FY2021 | Dec 31, 2021 | -438.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -38.1% | −33.6 |
| Q1 FY2026 | Mar 31, 2026 | -494.2% | −481.1 |
| Q4 FY2025 | Dec 31, 2025 | -3.8% | +20.1 |
| Q3 FY2025 | Sep 30, 2025 | 2.2% | +17.9 |
| Q2 FY2025 | Jun 30, 2025 | -4.6% | +27.1 |
| Q1 FY2025 | Mar 31, 2025 | -13.2% | +23.4 |
| Q4 FY2024 | Dec 31, 2024 | -23.9% | +27.3 |
| Q3 FY2024 | Sep 30, 2024 | -15.8% | +33.7 |
| Q2 FY2024 | Jun 30, 2024 | -31.6% | +98.9 |
| Q1 FY2024 | Mar 31, 2024 | -36.5% | +153.6 |
| Q4 FY2023 | Dec 31, 2023 | -51.3% | +102.7 |
| Q3 FY2023 | Sep 30, 2023 | -49.4% | +234.5 |
| Q4 FY2022 | Dec 31, 2022 | -130.5% | −1964.4 |
| Q3 FY2022 | Sep 30, 2022 | -190.1% | +752.0 |
| Q2 FY2022 | Jun 30, 2022 | -154.0% | +245.1 |
| Q1 FY2022 | Mar 31, 2022 | -283.9% | – |
| Q4 FY2021 | Dec 31, 2021 | 1833.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -942.2% | – |
| Q2 FY2021 | Jun 30, 2021 | -399.0% | – |
See a number that looks wrong?